Patient 6 and patient 10 CAR-NK study
RNA-seq (gene expression) · human · 236 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 236 samples: 236 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE224915_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA933117 and SRA study SRP421654. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 236 sample titles: 236 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7035469 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G10_S274
- GSM7035470 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G11_S275
- GSM7035471 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G12_S276
- GSM7035472 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G1_S265
- GSM7035473 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G2_S266
- GSM7035474 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G3_S267
- GSM7035475 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G4_S268
- GSM7035476 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G5_S269
- GSM7035477 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G6_S270
- GSM7035478 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G7_S271
- GSM7035479 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G8_S272
- GSM7035480 MDanderson_Bcells_patient6_timepoint1_sc_smartseq_pl2_G9_S273
- GSM7035481 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D10_S334
- GSM7035482 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D11_S335
- GSM7035483 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D12_S336
- GSM7035484 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D1_S325
- GSM7035485 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D2_S326
- GSM7035486 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D3_S327
- GSM7035487 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D4_S328
- GSM7035488 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D5_S329
- GSM7035489 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D6_S330
- GSM7035490 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D7_S331
- GSM7035491 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D8_S332
- GSM7035492 MDanderson_Bcells_patient6_timepoint2_sc_smartseq_pl2_D9_S333
- GSM7035493 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H10_S382
- GSM7035494 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H11_S383
- GSM7035495 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H12_S384
- GSM7035496 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H1_S373
- GSM7035497 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H2_S374
- GSM7035498 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H3_S375
- GSM7035499 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H4_S376
- GSM7035500 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H5_S377
- GSM7035501 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H6_S378
- GSM7035502 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H7_S379
- GSM7035503 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H8_S380
- GSM7035504 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowD_H9_S381
- GSM7035505 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowE_H10_S286
- GSM7035506 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowE_H11_S287
- GSM7035507 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowE_H12_S288
- GSM7035508 MDanderson_Bcells_patient6_timepoint3_sc_smartseq_pl2rowE_H1_S277
+ 196 more — browse all 236 samples with per-sample file links →
- GSE310267 OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumors 36 samples shares car-nk
- GSE276388 The effects of PD-L1 and SCE over-expression on CAR-NK cell cytotoxicity against tumor cells 32 samples shares car-nk
- GSE278506 Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with enhanced PI3K/AKT/mTOR signal signature 12 samples shares car-nk
- GSE298054 Non-viral CISH locus-specific integrated IL-15-armored CAR-NK cells achieve potent anti-tumor efficacy via adaptive NK cell differentiation 6 samples shares car-nk
- GSE306760 2B4 Co-Stimulation and Dasatinib Modulation Enhance Anti-CD19 CAR-NK Cell Cytotoxicity 6 samples shares car-nk
- GSE270430 Allogeneic HSPC-engineered CD33-targeting CAR-NKT cells synergize with hypomethylating agents for effective and safe treatment of myeloid malignancies 4 samples shares car-nk
- GSE307972 Anti-CD19 CAR-NK cells coexpressing GITRL to enhance antitumor activity for the treatment of leukemias and lymphomas. 4 samples shares car-nk
- GSE326791 CAR-NKT cells induce low cytokine release syndrome by targeting hyperinflammatory macrophages with mitigation from GM-SCF inhibition 2 samples shares car-nk
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.